Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW confirms 100th participant in XanaMIA AD trial & interim analysis timeline

ACW announces that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee in January 2026

View announcement

ACW accesses up to $13.8m in non-dilutive R&D tax incentive funding

ACW has received an initial tranche of $3.0m in non-dilutive funding from Endpoints Capital under a funding facility secured against the Company’s FY25 Research and Development Tax Incentive (“RDTI”), with conditional commitments for a further $2.9m to be made available next quarter in relation to the final full year FY25 RDTI, and up to $7.9m conditionally approved against the forecast FY26 RDTI

View announcement

ACW CCO & CMO present at BIO partnering conference in Boston

Chief Commercial Officer, Mr Andy Udell, and Chief Medical Officer, Dr Dana Hilt MD, are conducting meetings and delivering a company presentation at the BIO International Convention (BIO 2025) in Boston, USA
They are engaging with international investors and potential biopharma partners throughout the conference to discuss ACW’s latest advancements and the potential of our lead asset, Xanamem®.

View announcement & slides

Courier Mail article

The Courier Mail has published an article discussing the XanaMIA Alzheimer’s trial and the potential for Xanamem to become the “holy grail” in the quest to find a treatment for the disease.

View article

Clinical Trials Science Forum webinar recording posted on ACW YouTube channel

ACW’s CMO Dr Dana Hilt and guest A/Prof Michael Woodward from Austin Health lead a highly informative ‘plain English’ presentation and panel discussion that reviews the scope of leading current and potential treatments in development for Alzheimer’s disease & the ongoing significant unmet medical need for effective therapies. Then, Chief Commercial Officer, Andy Udell, outlines what commercialization planning means for a company like Actinogen.

View webinar recording

ACW Clinical Trials Science Forum slides

This announcement includes the slide presentation by ACW CMO Dana Hilt, CCO Andy Udell and A/Prof Michael Woodward from Austin Health in a webinar on the latest developments in the quest for effective Alzheimer’s treatments and how ACW is preparing for the future commercialization of its novel once-a-day oral medication, Xanamem.

View announcement & slides

Latest Summary Corporate Presentation

July 2025

View Presentation

The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting

Find Out More

Check for eligibility and join this trial in Australia or the USA

The Xanamem^® Pipeline

Alzheimer’s
Disease

Major Depressive
Disorder

Fragile X
Syndrome

Diseases to be studied

Phase 2 placebo-controlled trials

Outlook

Cognitive impairment in early

Alzheimer’s Disease

Find out more

Biomarker analysis in patients with mild AD

Cognitive benefit in patients with early stages of AD

Pivotal trials focused on cognitive enhancement

Diseases to be studied

Phase 2 placebo-controlled trials

Outlook

Depression

with cognitive impairment

Find out more

Depression and cognitive impairment

Pivotal trials assessing both depression and cognitive impairment

Diseases to be studied

Phase 2 placebo-controlled trials

Outlook

Anxiety, sleep &
behavioral problems in

Fragile X Syndrome

Find out more

Proof of concept in adolescent and young adult males

Pending alternative funding e.g. partnerships or grants

The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting

Find Out More

Check for eligibility and join this trial in Australia or the USA

Latest News
View all news

Latest Summary Corporate Presentation

July 2025

View Presentation

01 Jul 2025	Herald Sun	Once-a-day pill milestone – Trials on Alzheimer’s wonder drug show ‘definite improvement’ in patients
30 Jun 2025	Nine News Melbourne	Alzheimer’s trial – Melbourne hospitals play key role
30 Jun 2025	PR Newswire	Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline
04 Jun 2025	Courier Mail	Alzheimer’s wonder drug shows promise
15 May 2025	Webcast Video Recording	ACW Clinical Trials Science Forum 2025 – The critical importance of preparing for commercialization [1.00 hr]

Stay updated

If you would like to receive our latest news and updates, you can join our email distribution list. Simply register your details.

Investors View Investor Centre

Learn more

ASX Announcements

View all ASX Announcements

Latest results

2024 Full Year Financial results

View

Analyst REPORTS

View all Analyst Reports

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW confirms 100th participant in XanaMIA AD trial & interim analysis timeline

ACW accesses up to $13.8m in non-dilutive R&D tax incentive funding

ACW CCO & CMO present at BIO partnering conference in Boston

Courier Mail article

Clinical Trials Science Forum webinar recording posted on ACW YouTube channel

ACW Clinical Trials Science Forum slides

Latest Summary Corporate Presentation

The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting

The Xanamem® Pipeline

Alzheimer’s Disease

Depression

Fragile X Syndrome

The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting

Latest News View all news

Latest Summary Corporate Presentation

Stay updated

Investors View Investor Centre

ASX Announcements

Latest results

Analyst REPORTS

The Xanamem^® Pipeline

Latest News
View all news